<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222531</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17020069</org_study_id>
    <nct_id>NCT03222531</nct_id>
  </id_info>
  <brief_title>Expanding the Pool in Orthotopic Heart Transplantation</brief_title>
  <official_title>Expanding the Pool in Orthotopic Heart Transplantation: The Use of Hepatitis C Positive Donor Hearts in Hepatitis C Negative Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mary E. Keebler, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, pilot trial to test the safety and efficacy of transplantation of&#xD;
      hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV&#xD;
      Ab+/NAT+) donors to HCV seronegative recipients on the heart transplant waitlist. Treatment&#xD;
      and prophylaxis will be administered, using a transmission-triggered approach for the first&#xD;
      scenario (HCV Ab+/NAT- donors, arm 1) and a prophylaxis approach for the later scenario (HCV&#xD;
      Ab+/NAT+ donors, arm 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single center, pilot, open-label study of transplantation of hearts of&#xD;
      HCVAb+ donors to HCVAb- recipients with subsequent therapy with sofosbuvir/velpatasvir&#xD;
      (Epclusa®). Recipients of a heart from HCVAb+/NAT- donors is ARM 1 or the&#xD;
      transmission-triggered arm of the study. In this arm, the study will monitor transmission of&#xD;
      HCV by measuring HCV RNA in heart transplant recipients. If HCV RNA is detected, indicating&#xD;
      transmission of HCV, recipients will be treated with sofosbuvir/velpatasvir (Epclusa®) for 12&#xD;
      weeks. Virological response will be assessed at 4 weeks, end of treatment and 12 weeks after&#xD;
      completion of therapy.&#xD;
&#xD;
      Recipients of a heart from HCVAb+/NAT+ donors will be in ARM 2 or the prophylaxis arm of the&#xD;
      study. In this arm, patients will be started on a 12-week course of sofosbuvir/velpatasvir&#xD;
      (Epclusa®) on post-operative day 1 and will undergo close monitoring of HCV RNA for evidence&#xD;
      of transmission as well as monitoring of adverse events from therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Rate of adverse events due to sofosbuvir/velpatasvir (Epclusa) in patients in each experimental group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV free at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of participants in each experimental group who are free of HCV at 1 year following transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transmission rate of HCV from HCVAb+/NAT- donors to HCVAb- recipients</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of allograft rejection</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of graft loss</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waitlist time after enrollment</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Heart Transplant</condition>
  <condition>Cardiac Transplant</condition>
  <arm_group>
    <arm_group_label>HCV seropositive non-viremic (HCV Ab+/NAT-) donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV seropositive non-viremic (HCV Ab+/NAT-) donor hearts to HCV seronegative recipients.&#xD;
Heart recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.&#xD;
Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).&#xD;
Intervention: Drug: sofosbuvir/velpatasvir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV seropositive viremic (HCV Ab+/NAT+) donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV seropositive viremic (HCV Ab+/NAT+) donor hearts to HCV seronegative recipients.&#xD;
Starting post-operative day 1, heart recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).&#xD;
Intervention: Drug: sofosbuvir/velpatasvir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir/velpatasvir</intervention_name>
    <description>Drug: sofobuvir/velpatasvir</description>
    <arm_group_label>HCV seropositive non-viremic (HCV Ab+/NAT-) donor</arm_group_label>
    <arm_group_label>HCV seropositive viremic (HCV Ab+/NAT+) donor</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (recipients):&#xD;
&#xD;
          -  End stage heart failure&#xD;
&#xD;
          -  Age ≥ 18 and &lt;71 years&#xD;
&#xD;
          -  Listed heart transplant at UPMC&#xD;
&#xD;
          -  Have panel reactive antibody level of &lt;98%&#xD;
&#xD;
          -  No obvious contraindication to liver transplant&#xD;
&#xD;
          -  Able to travel to UPMC for routine post-transplant visits and study visits for a&#xD;
             minimum of 12 months after transplantation&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  Be willing to use a contraceptive method for a year after transplant&#xD;
&#xD;
        Inclusion criteria (donors):&#xD;
&#xD;
          -  HCV antibody positive&#xD;
&#xD;
          -  HCV NAT negative or positive&#xD;
&#xD;
          -  Acceptable cardiac function for donation&#xD;
&#xD;
        Exclusion criteria (recipients):&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  HCVAb or HCV RNA positive&#xD;
&#xD;
          -  Presence of behavioral risk factors for contracting HCV. These behavioral risk factors&#xD;
             are current injection drug use, current intranasal illicit drug use, current&#xD;
             percutaneous/parenteral exposures in an unregulated setting.&#xD;
&#xD;
          -  Hepatitis B surface antigen positive&#xD;
&#xD;
          -  History of liver cirrhosis&#xD;
&#xD;
          -  Persistently elevated liver transaminases, defined as ALT/AST at least 3 times the&#xD;
             upper limit of normal for a minimum of 3 consecutive months&#xD;
&#xD;
          -  Waitlisted for a multi-organ transplant&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Known allergy to sofosbuvir/velpatasvir&#xD;
&#xD;
          -  Any condition, psychiatric or physical, that in the opinion of the investigator would&#xD;
             make it unsafe to proceed with transplantation or interfere with the ability of the&#xD;
             subject to participate in the study&#xD;
&#xD;
          -  Ongoing therapy with amiodarone for atrial or ventricular arrhythmia Prescribed use of&#xD;
             Amiodarone&#xD;
&#xD;
        Exclusion criteria (donors):&#xD;
&#xD;
          -  Confirmed HIV positive (positive HIV-1 antibody, positive HIV-2 antibody, positive p24&#xD;
             antigen and/or positive HIV NAT)&#xD;
&#xD;
          -  Confirmed HBV positive (positive hepatitis B surface antigen and/or HBV NAT) Known&#xD;
             ongoing therapy for HCV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Sciortino, MD</last_name>
    <phone>412-648-3202</phone>
    <email>sciortinocm@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Traci McGaha, RN</last_name>
    <phone>412-692-4828</phone>
    <email>mcgahatl4@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Sciortino, MD</last_name>
      <phone>412-647-6636</phone>
      <email>sciortinocm@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Sciortino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Mary E. Keebler, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

